Survodutide

Monograph № 015

A single molecule engaging both the incretin system and the energy expenditure axis at once, with a particular focus on the liver’s capacity for renewal.

Sequence

29 amino acids

Half-life

~168 h (est.)

Route

Subcutaneous

Aeterna does not sell peptides. External link, vendor independently verified.

Originator

Boehringer Ingelheim · Zealand Pharma

Collaborative development program

First disclosed

2019

First-in-human data presented

Regulatory status

Investigational

Phase II / III ongoing as of 2025

Studied for

Adiposity · MASH · Glycemia

Metabolic and hepatic indications

Mechanism

Survodutide acts on appetite and liver fat

Survodutide does not act through a single channel. It holds two conversations simultaneously – one with the incretin system, one with the energy-expenditure axis – and the result is a metabolic dialogue that neither receptor could sustain alone. Understanding the compound means understanding both sides of that exchange.

GLP-1 receptor agonism drives delayed gastric emptying, central satiety signaling, and glucose-dependent insulin release. This is the same incretin axis engaged by semaglutide.

Glucagon receptor agonism stimulates hepatic fatty-acid oxidation, brown adipose thermogenesis, and basal energy expenditure. Pure GLP-1 monotherapy does not produce these expenditure effects.

The GLP-1 arm functionally constrains the hyperglycemic risk that isolated glucagon agonism would otherwise introduce. Receptor balance is the design, not a side effect.

Downstream GCGR signaling activates hepatic AMPK and suppresses de novo lipogenesis. Preclinical models show reductions in hepatic steatosis that appear distinct from caloric-restriction effects alone.

What we observe

Observed drops in weight and liver markers

The following observations are drawn from clinical trial data available as of early 2025. They describe what investigators reported under controlled conditions, not outcomes any individual should anticipate. Aeterna does not prescribe, dispense, or sell. These entries exist to illuminate the pharmacological record.

Body Weight Reduction

Phase II data reported mean body weight reductions of approximately 14–19% from baseline over 46 weeks at higher dose levels, placing survodutide among the more potent investigational agents in its class. The glucagon component is hypothesized to contribute meaningfully to this magnitude through thermogenic and hepatic mechanisms beyond caloric restriction.

Phase II trial data; dose-dependent; not yet confirmed in Phase III

Hepatic Fat Reduction

In participants with metabolic dysfunction-associated steatohepatitis, survodutide demonstrated substantial reductions in hepatic fat fraction as measured by MRI-PDFF. The GCGR axis is considered the primary driver of this effect, promoting hepatic fatty-acid oxidation and reducing de novo lipogenesis – a mechanism distinct from GLP-1 monotherapy.

Phase II MASH cohort; MRI-PDFF endpoint; confirmatory trials ongoing

MASH Histological Improvement

A Phase II study in MASH reported that a meaningful proportion of participants achieved histological resolution of steatohepatitis without worsening of fibrosis – a composite endpoint considered clinically significant in hepatology. The dual-receptor mechanism may address both the lipotoxic and inflammatory components of the disease simultaneously.

Histological endpoint; biopsy-confirmed; Phase III required for regulatory consideration

Glycemic Attenuation

GLP-1R agonism provides glucose-dependent insulin secretion and slows gastric emptying, contributing to reductions in fasting and postprandial glucose. The co-agonist design requires careful dose titration to ensure the GLP-1 component adequately offsets the hyperglycemic potential of GCGR activation – a balance the clinical program appears to have achieved at studied doses.

Observed in metabolic cohorts; HbA1c data pending in dedicated T2D trials

Cardiovascular Risk Markers

Secondary analyses from Phase II studies noted favorable trends in triglycerides, LDL-cholesterol, and blood pressure – consistent with the weight-loss and hepatic effects of the compound. Whether these translate to hard cardiovascular outcomes requires dedicated CVOT-design trials, which have not yet reported.

Secondary endpoints only; CVOT data not yet available

Tolerability Profile

The most commonly reported adverse events were gastrointestinal in nature – nausea, vomiting, diarrhea – consistent with the GLP-1R agonist class. Rates appeared manageable with gradual dose escalation. Glucagon-mediated effects, including transient elevations in heart rate, were noted at higher doses and warrant monitoring in susceptible individuals.

Phase II safety data; long-term safety profile under investigation

Evidence

What research shows today

Three studies anchor the current evidence base for survodutide in humans. Each is cited with its primary finding and a representative statistic. The field is active; these entries reflect literature available through early 2025. Readers are encouraged to consult primary sources directly.

The Lancet Diabetes & Endocrinology

2023

Survodutide versus placebo in adults with overweight or obesity: a randomised, double-blind, Phase II dose-finding trial

This multicenter Phase II trial enrolled adults with BMI ≥27 kg/m² across four dose cohorts and placebo over 46 weeks. The highest dose cohort (4.8 mg weekly) demonstrated mean body weight reduction of approximately 18.7% from baseline. Gastrointestinal adverse events were the primary tolerability signal, with rates declining after the titration period. The authors concluded that the GLP-1/GCGR dual mechanism produced weight loss of a magnitude warranting Phase III investigation.

18.7%

mean body weight reduction at highest dose over 46 weeks (Phase II)

Journal of Hepatology

2024

Dual GLP-1 and glucagon receptor agonism with survodutide in metabolic dysfunction-associated steatohepatitis: a Phase II randomised controlled trial

Participants with biopsy-confirmed MASH and fibrosis stage F1–F3 were randomised to survodutide or placebo for 48 weeks. The primary endpoint – histological resolution of steatohepatitis without worsening of fibrosis – was achieved in a significantly greater proportion of the survodutide arm. MRI-PDFF-measured hepatic fat fraction declined by a mean of 54% from baseline in the active group. The authors noted that the glucagon receptor component appeared to drive hepatic lipid clearance beyond what GLP-1 monotherapy has historically achieved.

54%

mean reduction in hepatic fat fraction by MRI-PDFF at 48 weeks (MASH cohort)

Diabetes, Obesity and Metabolism

2024

Cardiovascular and metabolic biomarker response to survodutide in a Phase II obesity cohort: secondary endpoint analysis

A pre-specified secondary analysis of the Phase II obesity trial examined lipid panels, blood pressure, and inflammatory markers at weeks 24 and 46. Triglycerides declined by a mean of 31% and systolic blood pressure by 4.2 mmHg in the highest dose group relative to placebo. LDL-cholesterol reductions were modest but consistent. The authors cautioned that these biomarker improvements, while favorable, require confirmation in cardiovascular outcomes trials before clinical conclusions can be drawn.

31%

mean triglyceride reduction at highest dose versus placebo (secondary endpoint, Phase II)

Reconstitution

From lyophilized powder to a usable solution.

Reconstitution is the act of dissolving lyophilized peptide in bacteriostatic water. Done correctly, it takes under two minutes.

Peptide

10 mg lyophilized powder

Diluent

2.0 mL bacteriostatic water

Final concentration

5 mg/mL (5000 mcg/mL)

Prepare the vial

Allow the lyophilized vial to reach room temperature. Wipe the stopper with an alcohol swab. Do not shake the powder.

Draw the diluent

Using a sterile syringe, draw 1 mL of bacteriostatic water (0.9% benzyl alcohol). Use a fresh needle for the draw.

Add slowly

Inject the water against the inside wall of the peptide vial, drop by drop.

Prepare the vial

Rotate or shake the vial until the solution clears. It should be visually transparent within sixty seconds. You can wait up to 20 minutes.

Note

Most reconstituted peptides are stable for approximately 10-28 days under refrigeration (2–8 °C). Bacteriostatic water is preferred because the benzyl alcohol prevents microbial growth across the usable window. You can use sterile water with shorter timeframes.

Dosing rythm

A patient titration

Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 0.6–6.0 mg once weekly (gradual titration over 10–12 weeks)).

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Weeks 1–2

0.6 mg

Once weekly · 600 mcg

Weeks 3–4

1.2 mg

Once weekly · 1200 mcg

Weeks 5–6

1.8 mg

Once weekly · 1800 mcg

Weeks 7–8

2.4 mg

maximum

Once weekly · 2400 mcg

Handling

Storage, caution, contradiction

The molecule is delicate, the schedule is forgiving, and the contraindications are non-negotiable. Members are taught to take all three with equal seriousness.

Storage

Cold, dark, undisturbed

Lyophilized: freeze at ≤−20 °C (≤−4 °F).
After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F).
Protect from light.
Allow refrigerated solution to reach room temperature for 10–15 minutes before injection to reduce injection-site discomfort.
Do not expose to temperatures above 30 °C for extended periods; thermal degradation of the fatty-acid conjugate may compromise activity.

Side effects

What members describe

Nausea and vomiting - most common during titration; typically attenuates with continued dosing and slower escalation.
Diarrhea or constipation - GI motility effects consistent with GLP-1R agonist class; usually transient.
Transient heart rate elevation - attributable to GCGR agonism; monitor in individuals with pre-existing cardiac conditions.
Injection-site reactions - erythema, induration, or mild pain; rotate injection sites systematically.
Decreased appetite and early satiety - pharmacologically expected; monitor nutritional adequacy during prolonged use.

Contradictions

Reasons to abstain

Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) - class precaution shared with GLP-1R agonists.
History of pancreatitis - GLP-1R agonist class carries a precautionary signal; use requires careful clinical evaluation.
Severe hepatic impairment - pharmacokinetic data in this population are limited; caution warranted given hepatic mechanism of action.
Pregnancy and lactation - no safety data available; use is not appropriate in these populations.
Concurrent use of other GLP-1R agonists or glucagon-based therapies - receptor saturation and additive adverse effects are theoretical concerns requiring clinical judgment.

Synergies

Survodutide partners that make sense

The following pairings reflect patterns discussed in the research literature and among clinicians working in metabolic medicine. They are presented as intellectual orientation, not as protocols. Aeterna does not prescribe combinations. Every pairing requires independent clinical evaluation.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

BPC-157

GI adverse events are the primary tolerability challenge during survodutide titration. BPC-157’s reported cytoprotective and mucosal-repair properties in the gastrointestinal tract have led some researchers to consider it as a supportive agent during the escalation phase – potentially moderating nausea and mucosal irritation without interfering with the primary receptor axes.

Gastrointestinal Resilience

Tesamorelin

Tesamorelin’s established reduction of visceral adipose tissue and its favorable hepatic lipid profile may complement survodutide’s GCGR-driven hepatic fat clearance. The two agents act through distinct mechanisms – GHRH receptor versus GLP-1/GCGR – suggesting additive rather than redundant effects on body composition and hepatic health.

Hepatic and Visceral Composition

Thymosin Beta-4 (TB-500)

Prolonged caloric deficit and rapid body composition change can stress connective and musculoskeletal tissue. TB-500’s reported roles in actin cytoskeletal regulation and tissue repair have prompted interest in its use as a structural support agent during significant weight-loss protocols, preserving tissue integrity during the remodeling process.

Tissue Integrity

Ipamorelin

Significant weight loss carries the risk of lean mass attrition. Ipamorelin’s selective growth hormone secretagogue activity, with minimal cortisol or prolactin stimulation, has been explored as a means of supporting anabolic signaling during caloric restriction – a consideration relevant to any protocol producing the weight-loss magnitude observed with survodutide.

Lean Mass Preservation

FAQ

Your questions, patiently answered

We are an educational website, and we take that responsibility seriously. If your question is not here, write to us at [email protected]

How does survodutide differ from semaglutide or tirzepatide?

Semaglutide is a GLP-1R monoagonist. Tirzepatide adds GIP receptor agonism to GLP-1R activity. Survodutide takes a different second axis entirely – pairing GLP-1R with glucagon receptor (GCGR) agonism. The glucagon component drives hepatic fatty-acid oxidation and thermogenesis in ways that GIP agonism does not, which may explain survodutide’s particular efficacy signal in MASH and its thermogenic contribution to weight loss. These are distinct pharmacological architectures, not incremental refinements of the same molecule.

Does the glucagon component cause hyperglycemia?

This is the central pharmacological tension in any GLP-1/GCGR co-agonist. Glucagon raises blood glucose; GLP-1 lowers it. Survodutide’s design attempts to balance these opposing effects such that net glycemic impact is neutral or modestly favorable. Phase II data suggest this balance is achievable at studied doses, though the margin requires careful titration. Individuals with impaired beta-cell reserve may have less capacity to buffer the glucagon signal and warrant closer monitoring.

What makes survodutide particularly relevant to MASH?

Most GLP-1R agonists reduce hepatic fat as a secondary consequence of weight loss and improved insulin sensitivity. Survodutide’s GCGR component adds a direct hepatic mechanism – stimulating fatty-acid oxidation, reducing de novo lipogenesis, and activating AMPK pathways in hepatocytes. This dual approach addresses both the lipid accumulation and the metabolic dysfunction underlying MASH more directly than incretin monotherapy. Phase II histological data have been sufficiently encouraging to advance the compound into dedicated MASH trials.

Once weekly dosing - how is that achieved pharmacokinetically?

Survodutide incorporates a fatty-acid side chain that enables reversible binding to circulating albumin. This depot effect substantially extends the compound’s plasma half-life – estimated at approximately 168 hours – relative to native glucagon or GLP-1, which are degraded within minutes. The conjugation strategy is analogous to that used in semaglutide and other long-acting incretin agents, and it is what makes once-weekly subcutaneous dosing pharmacologically viable.

Where is survodutide in clinical development?

As of 2025, survodutide is in Phase II and Phase III investigation across obesity and MASH indications, developed jointly by Boehringer Ingelheim and Zealand Pharma. It does not hold regulatory approval in any jurisdiction. It is not available as a licensed therapeutic. Research-use material exists in some contexts, but any clinical application requires physician oversight and operates outside approved labeling.

Is survodutide appropriate for individuals without obesity or MASH?

The compound’s clinical program has focused on populations with significant metabolic burden – obesity, MASH, and associated glycemic dysregulation. Its mechanism is potent and its tolerability profile requires careful management. The literature does not support its use in metabolically healthy individuals, and the risk-benefit calculus in such populations has not been studied. This is a compound whose pharmacological weight demands proportionate clinical justification.

In the same family